Refractory Multiple Myeloma Treatment Development: Emerging Therapies and Clinical Trials
A new report details the ongoing research and development of novel therapies for refractory multiple myeloma, with over 75 companies engaged in pipeline drug development.
An in-depth report on the refractory multiple myeloma treatment landscape was released on October 13, 2026, from Albany, US. DelveInsight's analysis covers ongoing clinical and non-clinical research for over 75 companies and 80 pipeline drug candidates. Refractory multiple myeloma presents significant treatment challenges due to resistance to existing therapies.
Pfizer's Elrexfio (elranatamab-bcmm) demonstrated positive results in Phase III trials, meeting its primary endpoint for progression-free survival in patients unresponsive to prior treatments. Bristol Myers Squibb's Zenbexus™ (iberdomide), in combination with daratumumab and dexamethasone, also showed significant improvements in median progression-free survival.
The report highlights numerous other companies and drug development initiatives addressing the unmet needs in refractory multiple myeloma. Key players include MorphoSys, Janssen, Novartis, AbbVie, and Takeda. The pipeline features novel antibodies, cell therapies, and combination treatments.
Multiple myeloma is a cancer of plasma cells. Treatment is complicated by the development of resistance to current therapies. The development of new, effective treatments is crucial for improving patient outcomes.